Cancer Research Technology
Log in Register
Menu

Anti-CD22 [RFB-4]

Info

Catalogue Number 151335
Applications FACS IHC IF
Antigen/Gene or Protein Targets CD22
Reactivity Human
Relevance Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.
Host Mouse
Immunogen Tonsil lymphocytes
Subclass IgG1
Molecular Weight (kDa) 153
Myeloma Used P3X63Ag8
Recommended Growing Conditions DMEM + 5% FCS
Strain Balb/c
Notes Cytoplasmic antigen of mature B lymphocytes. >90% reactivity on peripheral B cells.
Research Area Adhesion, Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology

References: 8 entries

DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048.

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

Europe PMC ID: 16397048

Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328.

Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.

Europe PMC ID: 3263328

Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.

Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103.

Human B cell development. II. Subpopulations in the human fetus.

Europe PMC ID: 3871452

Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.

Europe PMC ID: 3918103


Add a reference

References: 8 entries

DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048.

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

Europe PMC ID: 16397048

Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328.

Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.

Europe PMC ID: 3263328

Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.

Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103.

Human B cell development. II. Subpopulations in the human fetus.

Europe PMC ID: 3871452

Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.

Europe PMC ID: 3918103


Add a reference

References: 8 entries

DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048.

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328.

Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.

Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452.

Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103.

Human B cell development. II. Subpopulations in the human fetus.

Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.


Add a reference


This reagent does not have any reviews at the moment.